Open Access

Progression of melanoma is suppressed by targeting all transforming growth factor‑β isoforms with an Fc chimeric receptor

  • Authors:
    • Shingo Kodama
    • Katarzyna Α. Podyma‑Inoue
    • Toshihiro Uchihashi
    • Kyoko Kurioka
    • Hitomi Takahashi
    • Akinari Sugauchi
    • Kazuki Takahashi
    • Toshihiro Inubushi
    • Mikihiko Kogo
    • Susumu Tanaka
    • Tetsuro Watabe
  • View Affiliations

  • Published online on: July 20, 2021     https://doi.org/10.3892/or.2021.8148
  • Article Number: 197
  • Copyright: © Kodama et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Melanoma is an aggressive type of cancer originating from the skin that arises from neoplastic changes in melanocytes. Transforming growth factor‑β (TGF‑β) is a pleiotropic cytokine and is known to contribute to melanoma progression by inducing the epithelial‑mesenchymal transition (EMT) program and creating an environment that favors tumor progression. There are three TGF‑β isoforms, TGF‑β1, TGF‑β2 and TGF‑β3, all of which engage in pro‑tumorigenic activities by activating SMAD signaling pathways. All TGF‑β isoforms activate signaling pathways by binding to their TGF‑β type I (TβRI) and type II (TβRII) receptors. Thus, effective targeting of all TGF‑β isoforms is of great importance. In the present study, chimeric proteins comprising the extracellular domains of TβRI and/or TβRII fused with the Fc portion of human immunoglobulin (IgG) were validated in the melanoma context. The Fc chimeric receptor comprising both TβRI and TβRII (TβRI‑TβRII‑Fc) effectively trapped all TGF‑β isoforms. Conversely, TβRII‑Fc chimeric receptor, that comprises TβRII only, was able to interact with TGF‑β1 and TGF‑β3 isoforms, but not with TGF‑β2, which is a poor prognostic factor for melanoma patients. Accordingly, it was revealed that TβRI‑TβRII‑Fc chimeric receptor suppressed the EMT program in melanoma cells in vitro induced by any of the three TGF‑β isoforms, as revealed by decreased expression of mesenchymal markers. Conversely, TβRII‑Fc chimeric receptor inhibited the EMT program induced by TGF‑β1 and TGF‑β3. In addition, it was established that tumor growth in subcutaneous mouse melanoma was inhibited by TβRI‑TβRII‑Fc chimeric receptor indicating that Fc chimeric receptor could be applied to modify the tumor microenvironment (TME) of melanoma. Therefore, designing of Fc chimeric receptors targeting TGF‑β signals that affect various components of the TME may result in the development of effective anti‑melanoma agents.

Related Articles

Journal Cover

September-2021
Volume 46 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kodama S, Podyma‑Inoue KΑ, Uchihashi T, Kurioka K, Takahashi H, Sugauchi A, Takahashi K, Inubushi T, Kogo M, Tanaka S, Tanaka S, et al: Progression of melanoma is suppressed by targeting all transforming growth factor‑β isoforms with an Fc chimeric receptor. Oncol Rep 46: 197, 2021
APA
Kodama, S., Podyma‑Inoue, K.Α., Uchihashi, T., Kurioka, K., Takahashi, H., Sugauchi, A. ... Watabe, T. (2021). Progression of melanoma is suppressed by targeting all transforming growth factor‑β isoforms with an Fc chimeric receptor. Oncology Reports, 46, 197. https://doi.org/10.3892/or.2021.8148
MLA
Kodama, S., Podyma‑Inoue, K. Α., Uchihashi, T., Kurioka, K., Takahashi, H., Sugauchi, A., Takahashi, K., Inubushi, T., Kogo, M., Tanaka, S., Watabe, T."Progression of melanoma is suppressed by targeting all transforming growth factor‑β isoforms with an Fc chimeric receptor". Oncology Reports 46.3 (2021): 197.
Chicago
Kodama, S., Podyma‑Inoue, K. Α., Uchihashi, T., Kurioka, K., Takahashi, H., Sugauchi, A., Takahashi, K., Inubushi, T., Kogo, M., Tanaka, S., Watabe, T."Progression of melanoma is suppressed by targeting all transforming growth factor‑β isoforms with an Fc chimeric receptor". Oncology Reports 46, no. 3 (2021): 197. https://doi.org/10.3892/or.2021.8148